Eng‐Huat Tan

Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer

Qingyu Zhou, Alex Sparreboom, Eng‐Huat Tan et al. · British Journal of Clinical Pharmacology · 2005 · 94 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II study of irinotecan (CPT‐11) as salvage therapy for advanced nasopharyngeal carcinoma

Donald Poon, Balram Chowbay, Yin‐Bun Cheung et al. · Cancer · 2004 · 53 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer

Aaron C. Tan, Gillianne Lai, Stephanie P.L. Saw et al. · Cancer · 2024 · 39 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

Eng‐Huat Tan, Wan‐Teck Lim, Myung‐Ju Ahn et al. · Clinical Pharmacology in Drug Development · 2018 · 26 citations · Full text

Medicine, Oncology, Pharmacology +17

Chemotherapy with or without radiotherapy in patients with locoregionally recurrent nasopharyngeal carcinoma

Zee‐Wan Wong, Eng‐Huat Tan, Swee‐Peng Yap et al. · Head & Neck · 2002 · 16 citations

Medicine, Oncology, Radiation Oncology +16